Of course, bona fide FcγR-independent authentic TNFR2 agonists, as developed in our study, are not useful when TNFR2 targeting is envisaged with the aim to trigger FcγR functions, e.g. deletion of Tregs by ADCC in tumor therapy. The gene discussed is TNFRSF1B; the disease is neoplasm.